group

The CIRM-funded Alpha Stem Cell Clinics are a network of top California medical centers. The Network specializes in delivering stem cell clinical trials to patients. The key to the Network’s success is the ability to accelerate the delivery treatments to patients through partnerships with patients, medical providers and clinical trial sponsors. These partnerships enable:

  • Patient-centered clinical trials with the highest standards of care and research
  • Strategic collaboration with academic and industry teams developing innovative stem cell therapies
  • Leveraging of resources to promote efficiency, acceleration and increased chances of success

CURRENTLY ENROLLING – ACTIVE TRIALS

  • Disease: Tongue Dysphagia
    Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia
    (NCT02838316)
    Sponsor: UC Davis Cook Myosite
    PI: Peter Belafsky, M.D.
  • Disease: Retinopathy
    Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
    (NCT01736059)
    Sponsor: UC Davis
    PI: Susanna Park, M.D.
  • Disease: Duchenne Muscular Dystrophy (DMD)
    A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Delivered Cells in Subjects with Duchenne Muscular Dystrophy (HOPE-2)
    (NCT03406780)
    Sponsor: Capricor
    PI: Craig McDonald, M.D.
  • Disease: Nasopharyngeal Carcinoma
    A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients
    (NCT02578641)
    Sponsor: TESSA
    PI: Mehrdad Abedi, M.D.
  • Disease: Neutropenia
    Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML
    (NCT03301597)
    Sponsor: CIRM Nohla
    PI: Mehrdad Abedi, M.D.
  • Disease: HIV & Non-Hodgkin's lymphoma (HIV-NHL)
    Gene Therapy in Treating Patients with Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
    (NCT02797470)
    Sponsor: CIRM
    PI: Mehrdad Abedi, M.D.

CLINICAL TRIALS IN PROCESS: PLEASE CHECK BACK

  • Disease: Kidney Transplant
    Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants
    (NCT03363945)
    Sponsor: Medeor Therapeutics
    PI: Junichiro Sageshima, M.D.
  • Disease: Non-Hodgkins Lymphoma
    Study of ET190L1-ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma
    (NCT03379493)
    Sponsor: Eureka
    PI: Mehrdad Abedi, MD
  • Disease: Renal Disease
    A Phase 3 Study Comparing the Utility of Human Acellular Vessels to Arteriovenous Fistula in Subjects with End Stage Renal Disease
    (NCT03183245)
    Sponsor: CIRM Humacyte
    PI: Junichiro Sageshima, M.D.
  • Disease: Epstein-Barr virus-Posttransplant lymphoproliferative disease (EBV-PTLD)
    Multicenter Expanded Access Protocol of ATA129 for Subjects with Epstein-Barr Virus-Associated Viremia or Malignancies for Whom there are No Appropriate Alternative Therapies ATA129-EBV-201
    (NCT02822495 )
    Sponsor: Atara Biotherapeutics
    PI: Mehrdad Abedi, M.D.
  • Disease: Epstein-Barr virus-Posttransplant lymphoproliferative disease (EBV-PTLD)
    ATA129 for Solid Organ Transplant Subjects With EBV-PTLD After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE) ATA129-EBV-302
    (NCT03394365)
    Sponsor: Atara Biotherapeutics
    PI: Mehrdad Abedi, M.D.
  • Disease: Muscle Injury following arthroplasty for HF
    Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty for Hip Fracture
    (NCT03451916)
    Sponsor: Pluristem
    PI: Mark Lee, M.D.
  • Disease: B-Cell Leukemia
    A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies
    (NCT03420183)
    Sponsor: CIRM UCSD
    PI: Joe Tuscano, M.D.
  • Disease: Advanced Cancer
    A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers KITE 718-301
     (NCT03139370)
    Sponsor: Kite
    PI: Mehrdad Abedi, M.D.
  • Disease: Glioblastoma
    Phase II Trial of Autologous Dendritic Cells Loaded with Autologous Tumor Associated Antigens (AV-GBM-1) as an Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma
    (NCT03400917)
    Sponsor: AIVITA Biomedical
    PI: Robert O’Donnell, M.D., Ph.D.
  • Disease: Burns
    An Open Label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Efficacy Of Singel or Multiple Applications of Stratagraft® Skin Tissue as an Alternative to Autografting Full-Thickness Complex Skin Defects STRATA2014
    (NCT03005054)
    Sponsor: Mallinckrodt Pharmaceuticals
    PI: Tina Palmieri, M.D.
  • Disease: Burns
    A Phase III Open-label, Controlled, Randomized, Multicenter Study Evaluating the Efficacy and Safety of StrataGraft Skin Tissue in Promoting Autologous Skin Tissue Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements and for Which Excision and Autografts Are Clinically Indicated STRATA2016
    (NCT03005106)
    Sponsor: Mallinckrodt Pharmaceuticals
    PI: Tina Palmieri, M.D.
  • Disease: Critical Limb Ischemia
    A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Derived Autologous Angiogenic Cell Precursor Therapy in Patients With Critical Limb Ischemia (ACP-CLI)
    (NCT02551679)
    Sponsor: Hemostemix
    PI: Matthew Mell, M.D.

Patients interested in participating in Stem Cell Clinical Trials please phone 916-703-9302